Our Featured Experts

Bruce D. Cheson, MD
Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL
Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).
Andrew L. Pecora, MD
Dr. Pecora on the Significant Results of CTLA-4 and PD-1 Combination in Multiple Myeloma
Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.
Oncology Specialists
Publication Bottom Border
Border Publication